US 11,740,240 B2
Immunoassay for SARS-CoV-2 neutralizing antibodies and materials therefor
Qian Gao, Concord, CA (US); Ravi Kaul, Davis, CA (US); Shuxia Zhou, Benicia, CA (US); and Roger P. Walker, Benicia, CA (US)
Assigned to BIO-RAD LABORATORIES, INC., Hercules, CA (US)
Filed by BIO-RAD LABORATORIES, INC., Hercules, CA (US)
Filed on Jul. 19, 2021, as Appl. No. 17/379,193.
Claims priority of provisional application 63/114,685, filed on Nov. 17, 2020.
Claims priority of provisional application 63/088,195, filed on Oct. 6, 2020.
Claims priority of provisional application 63/053,888, filed on Jul. 20, 2020.
Prior Publication US 2022/0018838 A1, Jan. 20, 2022
Int. Cl. G01N 33/569 (2006.01); G01N 21/64 (2006.01)
CPC G01N 33/56983 (2013.01) [G01N 21/6428 (2013.01); G01N 2021/6439 (2013.01); G01N 2333/165 (2013.01)] 21 Claims
OG exemplary drawing
 
1. A substrate comprising a population of particles or beads comprising two or more separate subpopulations of particles or beads, each subpopulation of particles or beads being distinguishable by a specific detectable parameter and each subpopulation of beads comprising a distinct SARS-CoV-2 spike protein variant or fragment thereof immobilized thereon and, optionally, a further subpopulation of beads comprising a SARS-CoV-2 spike protein or fragment thereof immobilized thereon.